PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY ROA • Segmentation by RoA • Comparison by RoA • Oral RoA – Market size and forecast 2017-2022 • Parenteral RoA – Market size and forecast 2017-2022 • Market opportunity by RoA PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • NAFLD therapeutics market in the Americas – Market size and forecast 2017-2022 • NAFLD therapeutics market in EMEA – Market size and forecast 2017-2022 • NAFLD therapeutics market in APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ALLERGAN • GlaxoSmithKline • Merck • Novartis • Pfizer PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global metabolic disorders therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition: Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global NAFLD therapeutics market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global NAFLD therapeutics market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition: Five forces 2017 Exhibit 18: Pipeline landscape by development phase 2017-2018 Exhibit 19: Late-stage pipeline molecules for the treatment of NAFLD 2017-2018 Exhibit 20: Global NAFLD therapeutics market – Market share by RoA 2017-2022 (%) Exhibit 21: Comparison by RoA Exhibit 22: Global NAFLD therapeutics market by oral RoA – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global NAFLD therapeutics market by oral RoA – Year-over-year growth 2018-2022 (%) Exhibit 24: Global NAFLD therapeutics market by parenteral RoA – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Global NAFLD therapeutics market by parenteral RoA – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by RoA Exhibit 27: Customer landscape Exhibit 28: Global NAFLD therapeutics market by geography – Market share 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: NAFLD therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: NAFLD therapeutics market in Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: NAFLD therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 34: NAFLD therapeutics market in EMEA – Year-over-year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: NAFLD therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 37: NAFLD therapeutics market in APAC – Year-over-year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: ALLERGAN: Overview Exhibit 46: ALLERGAN – Business segments Exhibit 47: ALLERGAN – Organizational developments Exhibit 48: ALLERGAN – Geographic focus Exhibit 49: ALLERGAN – Segment focus Exhibit 50: ALLERGAN – Key offerings Exhibit 51: ALLERGAN – Key customers Exhibit 52: GlaxoSmithKline: Overview Exhibit 53: GlaxoSmithKline – Business segments Exhibit 54: GlaxoSmithKline – Organizational developments Exhibit 55: GlaxoSmithKline – Geographic focus Exhibit 56: GlaxoSmithKline – Segment focus Exhibit 57: GlaxoSmithKline – Key offerings Exhibit 58: GlaxoSmithKline – Key customers Exhibit 59: Merck– Overview Exhibit 60: Merck– Business segments Exhibit 61: Merck– Organizational developments Exhibit 62: Merck– Geographic focus Exhibit 63: Merck– Segment focus Exhibit 64: Merck– Key offerings Exhibit 65: Merck– Key customers Exhibit 66: Novartis – Overview Exhibit 67: Novartis – Business segments Exhibit 68: Novartis – Organizational developments Exhibit 69: Novartis – Geographic focus Exhibit 70: Novartis – Segment focus Exhibit 71: Novartis – Key offerings Exhibit 72: Novartis – Key customers Exhibit 73: Pfizer: Overview Exhibit 74: Pfizer – Business segments Exhibit 75: Pfizer – Organizational developments Exhibit 76: Pfizer – Geographic focus Exhibit 77: Pfizer – Segment focus Exhibit 78: Pfizer – Key offerings Exhibit 79: Pfizer – Key customers

ALLERGAN GlaxoSmithKline Merck Novartis Pfizer